Advertisement

Schmerzmedizin

, Volume 35, Issue 3, pp 40–45 | Cite as

Migräneprophylaxe

Erenumab — Empfehlungen für die Praxis

  • Hartmut GöbelEmail author
  • Axe Heinze
  • Katja Heinze-Kuhn
  • Astrid Gendolla
  • Johannes Horlemann
DGS Deutsche Gesellschaft für Schmerzmedizin e. V.
  • 7 Downloads

Ernenumab ist der erste Antikörper, der zur Vorbeugung von Migräneattacken zugelassen wurde. Der folgende Artikel soll eine Übersicht darüber geben, welche Wirkung von Erneumab zu erwarten ist, für welche Patienten er geeignet und wie er in der Praxis anzuwenden ist.

Literatur

  1. 1.
    Steiner TJ et al. Migraine: the seventh disabler. Cephalalgia 2013;33:289–90CrossRefGoogle Scholar
  2. 2.
    Steiner TJ et al. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain 2014;15:31CrossRefGoogle Scholar
  3. 3.
    Göbel H. Die Kopfschmerzen. 3. Ausgabe. Berlin, Heidelberg: Springer; 2012Google Scholar
  4. 4.
    Hagen K et al. Headache as a risk factor for dementia: a prospective population-based study. Cephalalgia 2014;34:327–35CrossRefGoogle Scholar
  5. 5.
    GBD 2016 Disease and injury incidence and prevalence collaborators. global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1211- 59Google Scholar
  6. 6.
    Steiner TJ et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain 2018;19:17CrossRefGoogle Scholar
  7. 7.
    Wang SJ et al. Comorbidities of migraine. Front Neurol 2010;1:16CrossRefGoogle Scholar
  8. 8.
    Hu X et al. Migraine and the risk of stroke: an updated meta-analysis of prospective cohort studies. Neurol Sci 2017;38:33–40CrossRefGoogle Scholar
  9. 9.
    Linde M et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 2012;19:703–11CrossRefGoogle Scholar
  10. 10.
    Goadsby PJ et al. Pathophysiology of migraine: A disorder of sensory processing. Physiol Rev 2017;97:553–622CrossRefGoogle Scholar
  11. 11.
    Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol 2018;17:174–82CrossRefGoogle Scholar
  12. 12.
    Dodick DW. A phase-by-phase review of migraine pathophysiology. Headache 2018;58:Suppl 1:4–16CrossRefGoogle Scholar
  13. 13.
    Ong JJY et al. Recent advances in pharmacotherapy for migraine prevention: from pathophysiology to new drugs. Drugs 2018;78:411–37CrossRefGoogle Scholar
  14. 14.
    Ashina H et al. CGRP in human models of migraine. Handb Exp Pharmacol. online 13. Juni 2018 doi:10.1007/164_2018_128Google Scholar
  15. 15.
    Edvinsson L (2018) The CGRP pathway in migraine as a viable target for therapies. Headache 58 Suppl 1:33–47CrossRefGoogle Scholar
  16. 16.
    Edvinsson L et al. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 2018;14:338–50CrossRefGoogle Scholar
  17. 17.
    Holland PR. Foreword: The CGRP pathway and migraine prevention: reducing the burden of disease. Headache 2018;58 Suppl 1:1–3CrossRefGoogle Scholar
  18. 18.
    Maasumi K et al. CGRP and migraine: The role of blocking Calcitonin Gene-Related Peptide ligand and receptor in the management of migraine. Drugs 2018;78:913–28CrossRefGoogle Scholar
  19. 19.
    Messina R et al. CGRP - a target for acute therapy in migraine: Clinical data. Cephalalgia 2019;39:420–7CrossRefGoogle Scholar
  20. 20.
    Cauchi M et al. CGRP and migraine. J Neurol 2016;263:192–4Google Scholar
  21. 21.
    Deen M et al. Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain 2017;18:96 doi:10.1186/ s10194-017-0807-1CrossRefGoogle Scholar
  22. 22.
    Edvinsson L. The journey to establish CGRP as a migraine target: A retrospective view. Headache 2015;55:1249–55CrossRefGoogle Scholar
  23. 23.
    Fiala JL et al. Patent watch: Migraine therapies targeting the CGRP pathway: intellectual property landscape. Nat Rev Drug Discov 2016;15:8–9CrossRefGoogle Scholar
  24. 24.
    Karsan N et al. CGRP mechanism antagonists and migraine management. Curr Neurol Neurosci Rep 2015;15:25CrossRefGoogle Scholar
  25. 25.
    Khan S et al. CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data. Cephalalgia 2019;39:374–89CrossRefGoogle Scholar
  26. 26.
    Wrobel Goldberg S et al. Targeting CGRP: A new era for migraine treatment. CNS Drugs 2015;29:443–52CrossRefGoogle Scholar
  27. 27.
    Yuan H et al. CGRP monoclonal antibodies for migraine: rationale and progress. BioDrugs 2017;31:487–501CrossRefGoogle Scholar
  28. 28.
    Tepper SJ History and review of anti- Calcitonin Gene-Related Peptide (CGRP) therapies: From translational research to treatment. Headache 2018;58:Suppl 3:238–75CrossRefGoogle Scholar
  29. 29.
    Shi L et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the Calcitonin Gene-Related Peptide Receptor. J Pharmacol Exp Ther 2016;356:223–31CrossRefGoogle Scholar
  30. 30.
    Goadsby PJ et al. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990:28:183–7CrossRefGoogle Scholar
  31. 31.
    Cernuda-Morollon E et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 2013;81:1191–6CrossRefGoogle Scholar
  32. 32.
    Lassen LH et al. CGRP may play a causative role in migraine. Cephalalgia 2002;22:54–61CrossRefGoogle Scholar
  33. 33.
    Goadsby PJ et al. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993;33:48–56CrossRefGoogle Scholar
  34. 34.
    Olesen J et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004;350:1104–10CrossRefGoogle Scholar
  35. 35.
    Ho TW et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology 2014;83:958–66CrossRefGoogle Scholar
  36. 36.
    Goadsby PJ et al. A controlled trial of Erenumab for episodic migraine. N Engl J Med 2017;377:2123–32CrossRefGoogle Scholar
  37. 37.
    Tepper S et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, doubleblind, placebo-controlled phase 2 trial. Lancet Neurol 2017;16:425–34CrossRefGoogle Scholar
  38. 38.
    Reuter U et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebocontrolled, phase 3b study. Lancet 2018;392:2280–7CrossRefGoogle Scholar
  39. 39.
    www.fachinfo.de/api/fachinfo/pdf/022119
  40. 40.
    Depre C et al. A randomized, double-blind, placebo-controlled study to evaluate the effect of Erenumab on exercise time during a treadmill test in patients with stable angina. Headache 2018;58:715–23CrossRefGoogle Scholar
  41. 41.
    Göbel H et al. Gesundheitsverhalten von Migräne- und Kopfschmerzpatienten bei digitaler Therapiebegleitung mit der Migräne-App. Schmerz 2019;33:147–55CrossRefGoogle Scholar
  42. 42.
    Schwedt T et al. Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain 2018;19:92CrossRefGoogle Scholar
  43. 43.
    Ashina M et al. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study. Neurology 2017;89:1237–43CrossRefGoogle Scholar
  44. 44.
    www.g-ba.de/downloads/92-975-2734/2018-11-01_ Nutzenbewertung-IQWiG_ Erenumab-D-407.pdf.
  45. 45.
    Diener HC et al. Therapie der Migräneattacke und Prophylaxe der Migräne, S1-Leitlinie 2018. In: Deutsche Gesellschaft für Neurologie (Hrsg.) Leitlinien für Diagnostik und Therapie in der Neurologie. Online: www.dgn.org/leitlinien
  46. 46.
    Göbel H et al. Chronic migraine and headache by medication overuse. Evolution and revision of classification. Schmerz 2011;25:493–500CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  • Hartmut Göbel
    • 1
    Email author
  • Axe Heinze
    • 1
  • Katja Heinze-Kuhn
    • 1
  • Astrid Gendolla
    • 2
  • Johannes Horlemann
    • 3
  1. 1.Neurologisch-verhaltensmedizinische Schmerzklinik KielKielDeutschland
  2. 2.EssenDeutschland
  3. 3.KevelaerDeutschland

Personalised recommendations